511 related articles for article (PubMed ID: 31529324)
1. Comparison of clinical outcomes of different components of diabetic macular edema on optical coherence tomography.
Hu Y; Wu Q; Liu B; Cao D; Dong X; Zhang L; Li T; Yang X; Yu H
Graefes Arch Clin Exp Ophthalmol; 2019 Dec; 257(12):2613-2621. PubMed ID: 31529324
[TBL] [Abstract][Full Text] [Related]
2. MEASUREMENTS OF RETINAL FLUID BY OPTICAL COHERENCE TOMOGRAPHY LEAKAGE IN DIABETIC MACULAR EDEMA: A Biomarker of Visual Acuity Response to Treatment.
Santos AR; Alves D; Santos T; Figueira J; Silva R; Cunha-Vaz JG
Retina; 2019 Jan; 39(1):52-60. PubMed ID: 29077605
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of Intravitreal Ranibizumab for Diabetic Macular Edema with Serous Retinal Detachment.
Kaya M; Karahan E; Ozturk T; Kocak N; Kaynak S
Korean J Ophthalmol; 2018 Aug; 32(4):296-302. PubMed ID: 30091308
[TBL] [Abstract][Full Text] [Related]
4. Optical coherence tomography biomarkers DROL, PROS, SND, hyperreflective walls of foveal cystoid spaces as predictors of central macular thickness and visual acuity in diabetic macular edema treated with intravitreal ranibizumab.
Sardana A; Singh K; Singh A; Singh VK
Indian J Ophthalmol; 2024 May; 72(5):722-727. PubMed ID: 38648434
[TBL] [Abstract][Full Text] [Related]
5. VISUAL AND MORPHOLOGIC OUTCOMES OF INTRAVITREAL RANIBIZUMAB FOR DIABETIC MACULAR EDEMA BASED ON OPTICAL COHERENCE TOMOGRAPHY PATTERNS.
Seo KH; Yu SY; Kim M; Kwak HW
Retina; 2016 Mar; 36(3):588-95. PubMed ID: 26398695
[TBL] [Abstract][Full Text] [Related]
6. Visual Outcomes Following Intravitreal Ranibizumab for Diabetic Macular Edema in a Pro Re Nata Protocol from Baseline: A Real-World Experience.
James DGP; Mitkute D; Porter G; Vayalambrone D
Asia Pac J Ophthalmol (Phila); 2019; 8(3):200-205. PubMed ID: 31165603
[TBL] [Abstract][Full Text] [Related]
7. Effect of intravitreal bevacizumab based on optical coherence tomography patterns of diabetic macular edema.
Kim M; Lee P; Kim Y; Yu SY; Kwak HW
Ophthalmologica; 2011; 226(3):138-44. PubMed ID: 21822008
[TBL] [Abstract][Full Text] [Related]
8. Comparing the Efficacy of Bevacizumab and Ranibizumab in Patients with Diabetic Macular Edema (BRDME): The BRDME Study, a Randomized Trial.
Vader MJC; Schauwvlieghe AME; Verbraak FD; Dijkman G; Hooymans JMM; Los LI; Zwinderman AH; Peto T; Hoyng CB; van Leeuwen R; Vingerling JR; Moll AC; van Lith-Verhoeven JJC; Dijkgraaf MGW; Schlingemann RO;
Ophthalmol Retina; 2020 Aug; 4(8):777-788. PubMed ID: 32362552
[TBL] [Abstract][Full Text] [Related]
9. Dexamethasone for unresponsive diabetic macular oedema: optical coherence tomography biomarkers.
Bonfiglio V; Reibaldi M; Pizzo A; Russo A; Macchi I; Faro G; Avitabile T; Longo A
Acta Ophthalmol; 2019 Jun; 97(4):e540-e544. PubMed ID: 30318792
[TBL] [Abstract][Full Text] [Related]
10. Diabetic macular oedema treated with intravitreal anti-vascular endothelial growth factor - 2-4 years follow-up of visual acuity and retinal thickness in 566 patients following Danish national guidelines.
Hodzic-Hadzibegovic D; Sander BA; Monberg TJ; Larsen M; Lund-Andersen H
Acta Ophthalmol; 2018 May; 96(3):267-278. PubMed ID: 29240306
[TBL] [Abstract][Full Text] [Related]
11. OCT Angiography Biomarkers for Predicting Visual Outcomes after Ranibizumab Treatment for Diabetic Macular Edema.
Hsieh YT; Alam MN; Le D; Hsiao CC; Yang CH; Chao DL; Yao X
Ophthalmol Retina; 2019 Oct; 3(10):826-834. PubMed ID: 31227330
[TBL] [Abstract][Full Text] [Related]
12. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.
Callanan DG; Loewenstein A; Patel SS; Massin P; Corcóstegui B; Li XY; Jiao J; Hashad Y; Whitcup SM
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):463-473. PubMed ID: 27632215
[TBL] [Abstract][Full Text] [Related]
13. Aqueous Humor Cytokine Levels and Anatomic Response to Intravitreal Ranibizumab in Diabetic Macular Edema.
Hillier RJ; Ojaimi E; Wong DT; Mak MYK; Berger AR; Kohly RP; Kertes PJ; Forooghian F; Boyd SR; Eng K; Altomare F; Giavedoni LR; Nisenbaum R; Muni RH
JAMA Ophthalmol; 2018 Apr; 136(4):382-388. PubMed ID: 29522144
[TBL] [Abstract][Full Text] [Related]
14. Subfoveal choroidal thickness changes after intravitreal ranibizumab injections in different patterns of diabetic macular edema using a deep learning-based auto-segmentation.
Wang XN; Cai X; He S; Zhang X; Wu Q
Int Ophthalmol; 2023 Dec; 43(12):4399-4407. PubMed ID: 33783677
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the effect of ranibizumab and dexamethasone implant on serous retinal detachment in diabetic macular edema.
Demircan A; Ozkaya A; Alkin Z; Kemer B; Yesilkaya C; Demir G
J Fr Ophtalmol; 2018 Oct; 41(8):733-738. PubMed ID: 30213609
[TBL] [Abstract][Full Text] [Related]
16. Structural and functional assessment after intravitreal injection of ranibizumab in diabetic macular edema.
Fu Y; Wang P; Meng X; Du Z; Wang D
Doc Ophthalmol; 2017 Dec; 135(3):165-173. PubMed ID: 28756595
[TBL] [Abstract][Full Text] [Related]
17. Anatomical and functional responses in eyes with diabetic macular edema treated with "1 + PRN" ranibizumab: one-year outcomes in population of mainland China.
Lai K; Huang C; Li L; Gong Y; Xu F; Zhong X; Lu L; Jin C
BMC Ophthalmol; 2020 Jun; 20(1):229. PubMed ID: 32539744
[TBL] [Abstract][Full Text] [Related]
18. Predictive factors of better outcomes by monotherapy of an antivascular endothelial growth factor drug, ranibizumab, for diabetic macular edema in clinical practice.
Sato S; Shinoda H; Nagai N; Suzuki M; Uchida A; Kurihara T; Kamoshita M; Tomita Y; Iyama C; Minami S; Yuki K; Tsubota K; Ozawa Y
Medicine (Baltimore); 2017 Apr; 96(16):e6459. PubMed ID: 28422835
[TBL] [Abstract][Full Text] [Related]
19. Changes in choroidal thickness after anti-vascular endothelial growth factor treatment of diabetic macular edema, real-life data, 2-year results.
Savur F; Kaldırım H; Atalay K; Korkmaz Ş
Cutan Ocul Toxicol; 2021 Dec; 40(4):326-331. PubMed ID: 34275395
[TBL] [Abstract][Full Text] [Related]
20. Imaging retinal inflammatory biomarkers after intravitreal steroid and anti-VEGF treatment in diabetic macular oedema.
Vujosevic S; Torresin T; Bini S; Convento E; Pilotto E; Parrozzani R; Midena E
Acta Ophthalmol; 2017 Aug; 95(5):464-471. PubMed ID: 27775223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
